Does Ozempic Protect Bones? New Real-World Data Suggests Semaglutide Reduces Fracture Risk in Type 2 Diabetes

22 Jun Does Ozempic Protect Bones? New Real-World Data Suggests Semaglutide Reduces Fracture Risk in Type 2 Diabetes

Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss in Type 2 Diabetes

Dr. Norena Velasquez

MedicalResearch.com Interview with:
Jairo Norena Velasquez, MD
Associate Division Chief, Endocrinology Division
Alameda Health System
Oakland, California

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Type 2 diabetes is associated with a paradoxically elevated fracture risk — up to three times higher than the general population — despite normal or even elevated bone mineral density. The underlying problem is poor bone quality driven by chronic hyperglycemia, advanced glycation end-product accumulation, and increased cortical porosity. Compounding this, intentional weight loss — a cornerstone of diabetes treatment — can accelerate bone loss by reducing mechanical loading on the skeleton.

Semaglutide is one of the most effective weight-loss agents available, yet direct real-world comparisons of its skeletal effects against other active weight-loss therapies were lacking.

Using the Atropos Health Eos EHR database — 161 million US patients from 2016 to 2023 — we compared fracture incidence and BMI change in adults with type 2 diabetes initiating semaglutide versus dulaglutide, phentermine/topiramate, or bupropion/naltrexone, using high-dimensional propensity score matching (17,506 pairs per group).

Semaglutide was associated with greater weight loss (mean delta BMI −1.9 vs. −1.2 kg/m²; difference −0.72 kg/m², p < 0.001) and a 15% reduction in fracture incidence (HR 0.85, 95% CI 0.77–0.93; p < 0.001) over a mean follow-up of 3.6 years.

MedicalResearch.com: What might be the mechanism behind these findings?

Response: The finding that greater weight loss coincided with fewer fractures is counterintuitive, since weight loss typically reduces mechanical loading and promotes bone resorption. This suggests semaglutide may exert direct bone-protective effects beyond its metabolic actions. GLP-1 receptors are expressed on osteoblasts, and preclinical animal studies demonstrate that GLP-1 receptor activation stimulates bone formation and may improve collagen matrix quality — precisely what is compromised in type 2 diabetes. Systemically, better glycemic control reduces advanced glycation end-product accumulation in bone, and reductions in inflammation may suppress osteoclast-driven resorption. These mechanisms could impact fracture risk reduction.

MedicalResearch.com: What should readers take away from your report?

Response: Semaglutide appears to offer a dual benefit in type 2 diabetes: superior weight loss and a meaningful reduction in fracture risk compared to other active weight-loss therapies. For patients with type 2 diabetes who are also at elevated skeletal risk — such as older adults with obesity and poor glycemic control — semaglutide may be a particularly favorable therapeutic choice. Clinicians should recognize that bone health is an integral, often underappreciated dimension of comprehensive diabetes management, and that the choice of therapy can have real skeletal consequences.

Our study has some limitations. As with any observational study, causal inference requires caution, and prospective confirmation is needed.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: I hope this research motivates the implementation of randomized trials to confirm these findings and clarify the underlying mechanisms. Such trials should incorporate DEXA scanning alongside serial bone turnover markers to assess whether semaglutide shifts the remodeling balance toward net bone preservation. Future work should also determine whether this effect is semaglutide-specific or a broader GLP-1 receptor agonist class effect, whether it extends to patients using semaglutide for obesity without diabetes, and whether higher doses confer greater skeletal benefit.

MedicalResearch.com: Is there anything else you would like to add?

Response: Fractures in type 2 diabetes carry significant morbidity and mortality yet remain underscreened and underaddressed in routine diabetes care. I hope this study encourages clinicians to incorporate skeletal risk into treatment decision-making and also encourage monitoring of bone health in weight-loss programs.

Doctors may feel more confident choosing semaglutide for diabetic patients who need to lose weight but are worried about bone health. This work is an important early step toward understanding the impact of semaglutide-induced weight loss on bone health in patients with type 2 diabetes.

MedicalResearch.com: Any disclosures?

Response: The authors JAN, YM, DES, JYW and SHK declare no conflict of interest. CWP and GH are employed by Atropos Health. The views expressed are those of the authors and do not necessarily represent the views of the Endocrine Society.

Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on June 22, 2026 by Marie Benz MD FAAD